ACADIA Pharmaceuticals Inc. (ACAD)

ACADIA Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	210.52	194.43	120.62	153.21	331.8	194.47
Short-Term Investments	265.78	250.21	301.98	373.27	305.93	507.75
Cash & Cash Equivalents	476.29	444.64	422.59	526.48	637.73	702.22
Cash Growth	16.55%	5.22%	-19.73%	-17.45%	-9.18%	46.80%
Receivables	100.08	102.35	63.08	65.34	50.28	37.87
Inventory	66.64	40.45	11.56	14.1	9.68	6.34
Other Current Assets	32.28	28.69	10.7	11.91	19.92	13.82
Total Current Assets	675.3	616.13	507.94	617.82	717.62	760.25
Property, Plant & Equipment	58.65	56.47	61.59	66.32	56.44	12.7
Goodwill and Intangibles	110.2	65.49	0	0	1.11	2.59
Other Long-Term Assets	10.95	10.87	18.28	15.98	7.45	7.64
Total Long-Term Assets	179.81	132.83	79.88	82.3	65	22.93
Total Assets	855.1	748.96	587.81	700.12	782.62	783.18
Accounts Payable	19.33	17.54	12.75	6.88	8.49	7.22
Other Current Liabilities	311.27	236.71	112.88	89.19	97.47	67.6
Total Current Liabilities	330.6	254.25	125.63	96.07	105.97	74.83
Long-Term Debt	49.19	47.8	52.7	56.13	44.46	6.36
Other Long-Term Liabilities	11.27	15.15	9.07	7.03	5.18	2.86
Total Long-Term Liabilities	60.46	62.95	61.77	63.16	49.64	9.22
Total Liabilities	391.06	317.2	187.4	159.23	155.61	84.05
Total Debt	49.19	47.8	52.7	56.13	44.46	6.36
Debt Growth	-4.38%	-9.29%	-6.11%	26.24%	598.95%	-
Retained Earnings	-2,414.28	-2,430.84	-2,369.55	-2,153.58	-1,985.71	-1,704.12
Comprehensive Income	-0.23	0.02	-0.98	-0.19	0.04	0.3
Shareholders' Equity	464.04	431.76	400.41	540.89	627.01	699.14
Net Cash / Debt	427.1	396.84	369.9	470.35	593.27	695.86
Net Cash / Debt Growth	19.57%	7.28%	-21.36%	-20.72%	-14.74%	45.47%
Net Cash Per Share	2.56	2.42	2.29	2.93	3.77	4.73
Working Capital	344.7	361.87	382.31	521.76	611.65	685.42
Book Value Per Share	2.82	2.64	2.48	3.37	3.98	4.75

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).